Clinical trials: Lipids Metabolism
Hypercholesterolemia
Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)
The purpose of this study is to determine whether an investigational medication will be more effective than an approved medication in reducing cholesterol levels.
- Trial name
- NCT00092716
- Testing
- MK0653, ezetimibe / Duration of Treatment: 28 weeks, Comparator: atorvastatin / Duration of Treatment: 28 weeks
- Volunteers
- 655 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia
The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg) co-administered with all approved doses of atorvastatin in a double-blind comparison with placebo, AVE5530 alone and atorvastatin alone in the…
- Trial name
- NCT00741715
- Testing
- AVE5530, atorvastatin
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 1,736 people
- Sponsor
- Sanofi
Atherosclerotic Cardiovascular Disease
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with…
- Trial name
- OPTIMA (NCT07034690)
- Testing
- Educational Material, Standard of care
- Where
- United Arab Emirates
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Patients With Metabolic Syndrome
A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.
The purpose of this study was to study the effect of different combinations of fenofibrate and metformin on the cluster of metabolic syndrome (MetS) biochemical abnormalities, and to determine the dose combination allowing…
- Trial name
- NCT00703755
- Testing
- Fenofibrate /Metformin
- Where
- 101 sites in Canada, Finland and 7 more
- Volunteers
- 2,288 people
- Sponsor
- Solvay Pharmaceuticals
Hyperlipidemia
A Study to Evaluate COR-1004 in Adult Volunteers.
This research study is being done to see if a new, injectable drug called COR-1004 is safe for people to take. It will also help doctors find the right dose of the drug.
- Trial name
- NCT07229118
- Testing
- COR-1004
- Where
- 2 sites in New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Essential Hypertension, Hyperlipidemia
Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
The purpose of this study is to evaluate efficacy and safety of HL-040XC in patients with essential hypertension and hyperlipidemia
- Trial name
- NCT01541943
- Testing
- Atorvastatin, Losartan, HL-040XC
- Where
- South Korea
- Volunteers
- 356 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Dyslipidemias, Hypercholesterolemia
Cholesterol-lowering Effects of Plant Stanol Ester
Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented. LDL-cholesterol lowering efficacy of the ingredient administered in a smoothie is less well known.
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hyperlipidemias
- Trial name
- NCT02316808
- Testing
- Plant stanol ester
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Hypertension, Dyslypidaemia
Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome
This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.
- Trial name
- LesScore (NCT00821574)
- Testing
- Fluvastatin, Valsartan, Hydrochlorothiazide
- Volunteers
- 144 people
- Sponsor
- Novartis
Cardiovascular Disease
An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.
Sixteen healthy subjects will be randomized to each of the 3 parallel treatment groups. Eligible subjects will check in to the clinical unit on Day -2 and have 24-hr pharmacokinetic collections on Day -1 and on Day 1.
- Trial name
- NCT00996268
- Testing
- GSK2212836
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atherosclerosis, Hypercholesterolemia
Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)
The purpose of the study is to determine whether ezetimibe plus simvastatin will be more effective than simvastatin alone in preventing progression of atherosclerosis of the inner layer of the carotid artery.
- Conditions
- Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II
- Trial name
- ENHANCE (NCT00552097)
- Testing
- ezetimibe (plus simvastatin)
- Volunteers
- 720 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Special Drug Use-Results Survey of Lipitor Tablets
This study is to evaluate the controlling effect of atrovastatin on plasma lipid to achieve the category-specific targeted lipid levels.
- Trial name
- ALWAYS (NCT01446679)
- Testing
- atrovastatin
- Where
- 8 sites in Japan
- Volunteers
- 24,050 people
- Sponsor
- Astellas Pharma Inc
HYPERCHOLESTEROLEMIA
EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA
This research aims to evaluate the effect of CARDICHOL chronic consumption (12 weeks) on lipid metabolism and especially on blood LDL cholesterol in volunteers with moderate hypercholesterolemia.
- Trial name
- CARDICHOL 1 (NCT02657759)
- Testing
- CARDICHOL
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Direct Plantes
Hyperlipidemias
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels
The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.
- Trial name
- NCT00813527
- Testing
- Lapaquistat acetate and fenofibrate, Fenofibrate
- Where
- 36 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Takeda
Hypertriglyceridemia
An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients
1. Evaluation of the efficacy of Omacor® in Taiwanese hypertriglyceridemia patients 2. Evaluation of the safety of Omacor® in Taiwanese hypertriglyceridemia patients
- Trial name
- NCT01725646
- Testing
- Omacor®
- Where
- 4 sites in Taiwan
- Volunteers
- 253 people
- Sponsor
- Excelsior
Hypercholesterolemia, Dyslipidemia
Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin in patients with risk factors for heart disease.
- Trial name
- NCT00309738
- Testing
- pitavastatin, simvastatin
- Where
- 35 sites in Denmark, Netherlands and 2 more
- Volunteers
- 355 people
- Sponsor
- Kowa Research Europe
Vascular Diseases, Hypercholesterolemia
The Effect of Plant Sterols on Vascular Function
The main aim of the study is to investigate, in humans, the effect of plant sterols on vascular function by measuring flow-mediated dilation (FMD).
- Trial name
- NCT01803178
- Testing
- Plant Sterols
- Where
- Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Hypercholesterolemia, Dyslipidemia
Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
The purpose of this study is to determine the non-inferiority between two different FDC (fixed-dose combination), measuring LDL-Cholesterol levels, in high risk patients with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- LANCE (NCT01420549)
- Testing
- Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation., Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
- Where
- 7 sites in Brazil
- Volunteers
- 129 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Niemann-Pick Disease, Type C
Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease
This is a Phase-2, multicenter, multiple dose, open-label, 2-part evaluation study which will primarily assess the safety and tolerability of VTS-270 (2-hydroxypropyl beta-cyclodextrin [HP-β-CD]) in pediatric participants with…
- Trial name
- NCT03687476
- Testing
- VTS-270
- Sponsor
- Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Hypercholesteremia
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
- Trial name
- NCT00225589
- Testing
- Rosuvastatin calcium
- Where
- 57 sites in United States, Belgium and 6 more
- Volunteers
- 840 people
- Sponsor
- AstraZeneca
Hypercholesterolaemia
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in…
- Trial name
- NCT07610278
- Testing
- QCZ484, Inclisiran
- Where
- 29 sites in United States
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.